Trials / Conditions / Soft Tissue Sarcomas

Soft Tissue Sarcomas

23 registered clinical trials studyying Soft Tissue Sarcomas — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric a NCT07444619	M.D. Anderson Cancer Center	Phase 1
Withdrawn	Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable Hypervascular Pediatric Sof NCT07136571	University of Alabama at Birmingham	N/A
Completed	Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE NCT06535997	Hospices Civils de Lyon	—
Recruiting	IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) NCT06849986	Fudan University	Phase 2
Recruiting	A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tiss NCT06308419	M.D. Anderson Cancer Center	Phase 1
Recruiting	The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities NCT06593899	Fujian Medical University Union Hospital	Phase 2
Unknown	Gene Signatures Searching of Sensitivity/Resistance to Neoadjuvant Radiotherapy in Patients With Resectable ST NCT05739084	Centre Leon Berard	—
Active Not Recruiting	Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas NCT04425967	The Netherlands Cancer Institute	N/A
Recruiting	Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas NCT04506008	Vanderbilt-Ingram Cancer Center	Phase 2
Unknown	Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated NCT03946943	Di Wu	Phase 2
Completed	Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride NCT04223583	Henan Cancer Hospital	Phase 4
Withdrawn	Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas NCT03149120	NYU Langone Health	Phase 2
Terminated	A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumor NCT02536183	AeRang Kim	Phase 1
Recruiting	CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. NCT02789384	Institut Bergonié	N/A
Completed	Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas NCT02636725	Jonathan Trent, MD, PhD	Phase 2
Terminated	Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients NCT02575066	The Netherlands Cancer Institute	Phase 2
Completed	Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclo NCT02805725	Institut Bergonié	Phase 1 / Phase 2
Completed	RAD001 in Advanced Sarcoma NCT01830153	Asan Medical Center	Phase 2
Withdrawn	Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas NCT00881595	University of Florida	Phase 2
Unknown	11C-Acetate PET/CT Non-FDG-Avid Tumors NCT00687778	Tel-Aviv Sourasky Medical Center	—
Completed	Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced C NCT00423254	Mannkind Corporation	Phase 1
Completed	The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). NCT00385203	AstraZeneca	Phase 2
Completed	Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) NCT00276302	Infinity Pharmaceuticals, Inc.	Phase 1